A second major trial has strengthened the case for using SGLT2 inhibitors in patients with heart failure and a reduced ejection fraction (HFrEF) regardless of diabetes status. Results seen with empagliflozin in the EMPEROR-Reduced trial show that those seen previously with dapagliflozin in the DAPA-HF were no fluke, according to cardiologists presenting findings at European ...
EMPEROR-Reduced increases rationale for SGLT2 inhibitors as standard of care in HFrEF
By Michael Woodhead
1 Sep 2020